Glial activation is moderated by sex in response to amyloidosis but not to tau pathology in mouse models of neurodegenerative diseases.


Journal

Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974

Informations de publication

Date de publication:
14 Dec 2020
Historique:
received: 20 07 2020
accepted: 25 11 2020
entrez: 15 12 2020
pubmed: 16 12 2020
medline: 1 10 2021
Statut: epublish

Résumé

In vivo assessment of neuroinflammation by 18-kDa translocator protein positron-emission-tomography (TSPO-PET) ligands receives growing interest in preclinical and clinical research of neurodegenerative disorders. Higher TSPO-PET binding as a surrogate for microglial activation in females has been reported for cognitively normal humans, but such effects have not yet been evaluated in rodent models of neurodegeneration and their controls. Thus, we aimed to investigate the impact of sex on microglial activation in amyloid and tau mouse models and wild-type controls. TSPO-PET ( Wild-type mice showed an increased TSPO-PET signal over time (female +23%, male +4%), with a significant sex × age interaction (T = - 4.171, p < 0.001). The Aβ model App Female mice indicate sex-dependent microglia activation in aging and in response to amyloidosis but not in response to tau pathology. This calls for consideration of sex difference in TSPO-PET studies of microglial activation in mouse models of neurodegeneration and by extension in human studies.

Sections du résumé

BACKGROUND BACKGROUND
In vivo assessment of neuroinflammation by 18-kDa translocator protein positron-emission-tomography (TSPO-PET) ligands receives growing interest in preclinical and clinical research of neurodegenerative disorders. Higher TSPO-PET binding as a surrogate for microglial activation in females has been reported for cognitively normal humans, but such effects have not yet been evaluated in rodent models of neurodegeneration and their controls. Thus, we aimed to investigate the impact of sex on microglial activation in amyloid and tau mouse models and wild-type controls.
METHODS METHODS
TSPO-PET (
RESULTS RESULTS
Wild-type mice showed an increased TSPO-PET signal over time (female +23%, male +4%), with a significant sex × age interaction (T = - 4.171, p < 0.001). The Aβ model App
CONCLUSION CONCLUSIONS
Female mice indicate sex-dependent microglia activation in aging and in response to amyloidosis but not in response to tau pathology. This calls for consideration of sex difference in TSPO-PET studies of microglial activation in mouse models of neurodegeneration and by extension in human studies.

Identifiants

pubmed: 33317543
doi: 10.1186/s12974-020-02046-2
pii: 10.1186/s12974-020-02046-2
pmc: PMC7737385
doi:

Substances chimiques

Mapt protein, mouse 0
tau Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

374

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : BR4580/1-1
Organisme : Deutsche Forschungsgemeinschaft
ID : RO5194/1-1
Organisme : Deutsche Forschungsgemeinschaft
ID : EXC 2145 SyNergy

Références

Neurobiol Learn Mem. 2016 Nov;135:73-82
pubmed: 27377630
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
J Neuroinflammation. 2020 Jul 13;17(1):208
pubmed: 32660586
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006189
pubmed: 22229116
Brain Res. 2010 Dec 17;1366:233-45
pubmed: 20934413
N Engl J Med. 2010 Jan 28;362(4):329-44
pubmed: 20107219
Nat Neurosci. 2019 Feb;22(2):191-204
pubmed: 30617257
J Neurol Neurosurg Psychiatry. 2016 Jan;87(1):21-8
pubmed: 26384512
Nat Neurosci. 2014 May;17(5):661-3
pubmed: 24728269
Alzheimers Dement (N Y). 2015 Sep 1;1(2):103-110
pubmed: 26451386
Int J Mol Sci. 2017 Mar 04;18(3):
pubmed: 28273860
J Nucl Med. 2019 Dec;60(12):1787-1793
pubmed: 31302633
Int J Mol Sci. 2019 Jun 28;20(13):
pubmed: 31261683
J Neuroinflammation. 2018 Nov 6;15(1):307
pubmed: 30400912
Biol Sex Differ. 2011 Jul 11;2:7
pubmed: 21745355
J Cereb Blood Flow Metab. 2018 Feb;38(2):204-224
pubmed: 29256293
J Nucl Med. 2020 Dec;61(12):1825-1831
pubmed: 32414948
Trends Mol Med. 2019 Sep;25(9):741-749
pubmed: 31171460
Front Neurosci. 2016 Feb 29;10:45
pubmed: 26973442
Nature. 2019 Nov;575(7784):669-673
pubmed: 31748742
Dialogues Clin Neurosci. 2016 Dec;18(4):437-446
pubmed: 28179815
Alzheimers Dement. 2008 Sep;4(5):316-23
pubmed: 18790458
Nat Neurosci. 2020 Feb;23(2):167-171
pubmed: 31873194
J Neurosci. 2002 Nov 1;22(21):9340-51
pubmed: 12417659
Glia. 2006 Nov 1;54(6):485-98
pubmed: 16906540
J Nucl Med. 2017 Dec;58(12):1984-1990
pubmed: 28705919
Neuropathol Appl Neurobiol. 2014 Dec;40(7):833-43
pubmed: 24865638
J Nucl Med. 2016 Jun;57(6):954-60
pubmed: 26912428
Alzheimers Dement (Amst). 2020 Feb 13;12(1):e12007
pubmed: 32211502
Biochem J. 2018 Jan 2;475(1):75-85
pubmed: 29127254
Lancet Neurol. 2015 Apr;14(4):388-405
pubmed: 25792098
J Neurosci Res. 2017 Jan 2;95(1-2):671-680
pubmed: 27870425
Elife. 2020 Jun 08;9:
pubmed: 32510331
Brain Pathol. 1991 Apr;1(3):213-6
pubmed: 1669710
Front Neuroendocrinol. 2016 Oct;43:60-82
pubmed: 27651175
JAMA Neurol. 2014 Apr;71(4):505-8
pubmed: 24493463
Glia. 2020 Feb;68(2):280-297
pubmed: 31479168
JAMA Neurol. 2019 May 1;76(5):542-551
pubmed: 30715078
Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2329-2338
pubmed: 31363804
Alzheimers Dement. 2012 Jan;8(1):1-13
pubmed: 22265587

Auteurs

Gloria Biechele (G)

Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninstraße 15, 81377, Munich, Germany.

Nicolai Franzmeier (N)

Institute for Stroke and Dementia Research, University Hospital of Munich, LMU Munich, Munich, Germany.

Tanja Blume (T)

Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninstraße 15, 81377, Munich, Germany.
DZNE - German Center for Neurodegenerative Diseases, Munich, Germany.

Michael Ewers (M)

Institute for Stroke and Dementia Research, University Hospital of Munich, LMU Munich, Munich, Germany.
DZNE - German Center for Neurodegenerative Diseases, Munich, Germany.

Jose Medina Luque (JM)

DZNE - German Center for Neurodegenerative Diseases, Munich, Germany.

Florian Eckenweber (F)

Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninstraße 15, 81377, Munich, Germany.

Christian Sacher (C)

Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninstraße 15, 81377, Munich, Germany.

Leonie Beyer (L)

Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninstraße 15, 81377, Munich, Germany.

Francois Ruch-Rubinstein (F)

Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninstraße 15, 81377, Munich, Germany.

Simon Lindner (S)

Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninstraße 15, 81377, Munich, Germany.

Franz-Josef Gildehaus (FJ)

Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninstraße 15, 81377, Munich, Germany.

Barbara von Ungern-Sternberg (B)

Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninstraße 15, 81377, Munich, Germany.

Paul Cumming (P)

Department of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland.
School of Psychology and Counselling, Queensland University of Technology, Brisbane, Australia.

Peter Bartenstein (P)

Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninstraße 15, 81377, Munich, Germany.
Department of Neurology, Hannover Medical School, Hannover, Germany.

Axel Rominger (A)

Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninstraße 15, 81377, Munich, Germany.
Department of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland.

Günter U Höglinger (GU)

Institute for Stroke and Dementia Research, University Hospital of Munich, LMU Munich, Munich, Germany.
Department of Neurology, Technical University Munich, Munich, Germany.
Center of Neuropathology and Prion Research, University of Munich, Munich, Germany.

Jochen Herms (J)

Institute for Stroke and Dementia Research, University Hospital of Munich, LMU Munich, Munich, Germany.
Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
Department of Neurology, Hannover Medical School, Hannover, Germany.

Matthias Brendel (M)

Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninstraße 15, 81377, Munich, Germany. matthias.brendel@med.uni-muenchen.de.
Department of Neurology, Hannover Medical School, Hannover, Germany. matthias.brendel@med.uni-muenchen.de.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH